Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

, MRK

Merck

09:13
10/10/16
10/10
09:13
10/10/16
09:13

JPMorgan Euro & US pharma/biotech analysts hold analyst/industry conference call

European Healthcare Analysts Vosser and Gordon, along with U.S. and Specialty Pharmaceuticals Analyst Schott, discuss key takeaways from the European Society for Medical Oncology (ESMO) Conference on an Analyst/Industry conference call to be held on October 10 at 10 am.

BMY

Bristol-Myers

MRK

Merck

RHHBY

Roche

$30.49

-0.05 (-0.16%)

AZN

AstraZeneca

  • 19

    Oct

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

  • 10

    Nov

  • 16

    Nov

BMY Bristol-Myers

09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
MRK Merck

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
RHHBY Roche
$30.49

-0.05 (-0.16%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
AZN AstraZeneca

09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
AstraZeneca initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started AstraZeneca with an Overweight rating and GBP 60 price target.
10/07/16
PIPR
10/07/16
NO CHANGE
PIPR
Neutral
Piper still sees Clovis' rucaparib getting broader indication than Lynparza
Piper Jaffray analyst Steven Breazzano said the rucaparib response rates in platinum resistant and platinum refractory patients of 25% and 0%, respectively, reported by Clovis Oncology (CLVS) are lower than some may have been expecting and "seemingly negative on the surface." However, he continues to believe rucaparib will be approved in BRCA patients who have received 2+ lines of therapy, which is an earlier and broader patient population than assigned to competitor AstraZeneca's (AZN) Lynparza, he tells investors. The ultimate market potential and key to success is the maintenance setting, for which TESARO's (TSRO) niraparib is still best-positioned, adds Breazzano, who keeps a Neutral rating on Clovis shares.
09/13/16
EXAN
09/13/16
DOWNGRADE
EXAN
Neutral
AstraZeneca downgraded to Neutral from Outperform at Exane BNP Paribas

TODAY'S FREE FLY STORIES

AM

Antero Midstream Partners

16:21
01/16/18
01/16
16:21
01/16/18
16:21
Hot Stocks
Antero Midstream Partners increases dividend 7% to 36.5c »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

ESP

Espey Mfg

$24.55

-0.1092 (-0.44%)

16:21
01/16/18
01/16
16:21
01/16/18
16:21
Hot Stocks
Espey Mfg announces new three-year term for CEO Patrick Enright, Jr. »

Espey Mfg. &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTM

Quantum

$6.07

-0.07 (-1.14%)

, GUID

Guidance Software

16:20
01/16/18
01/16
16:20
01/16/18
16:20
Hot Stocks
Quantum appoints Patrick Dennis as CEO »

Quantum (QTM) announced…

QTM

Quantum

$6.07

-0.07 (-1.14%)

GUID

Guidance Software

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
01/16/18
01/16
16:20
01/16/18
16:20
Options
Closing CBOE SPX and VIX Index summary for January 16th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$335.16

-1.05 (-0.31%)

, ADNT

Adient

$82.18

-0.51 (-0.62%)

16:19
01/16/18
01/16
16:19
01/16/18
16:19
Hot Stocks
Boeing, Adient launch new company to design, build airplane seats »

Boeing (BA) and Adient…

BA

Boeing

$335.16

-1.05 (-0.31%)

ADNT

Adient

$82.18

-0.51 (-0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 29

    Jan

  • 31

    Jan

  • 21

    Feb

CLD

Cloud Peak

$5.31

-0.24 (-4.32%)

16:18
01/16/18
01/16
16:18
01/16/18
16:18
Hot Stocks
Cloud Peak Energy signs long-term coal export pact with JERA Trading »

Cloud Peak Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

GDEN

Golden Entertainment

$31.70

-0.48 (-1.49%)

16:18
01/16/18
01/16
16:18
01/16/18
16:18
Syndicate
Golden Entertainment files to sell 6.5M shares of common stock for holders »

J.P. Morgan and Morgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

16:18
01/16/18
01/16
16:18
01/16/18
16:18
Hot Stocks
Breaking Hot Stocks news story on A10 Networks »

A10 Networks down 2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

16:17
01/16/18
01/16
16:17
01/16/18
16:17
Earnings
A10 Networks reports preliminary Q4 adjusted EPS 5c-6c, consensus 3c »

Reports preliminary Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMT

Core Molding

$20.85

-0.49 (-2.30%)

16:17
01/16/18
01/16
16:17
01/16/18
16:17
Hot Stocks
Core Molding acquires Horizon Plastics for approximately $63M in cash »

Core Molding announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

16:17
01/16/18
01/16
16:17
01/16/18
16:17
Earnings
Aerohive cuts Q4 revenue view to roughly $37M from $40M-$42M, consensus $40.89M »

The Company expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

16:17
01/16/18
01/16
16:17
01/16/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$62.07

3.41 (5.81%)

, UNH

UnitedHealth

$233.29

4.65 (2.03%)

16:16
01/16/18
01/16
16:16
01/16/18
16:16
General news
On The Fly: Top stock stories for Tuesday »

Stocks opened sharply…

MRK

Merck

$62.07

3.41 (5.81%)

UNH

UnitedHealth

$233.29

4.65 (2.03%)

GE

General Electric

$18.21

-0.55 (-2.93%)

NSRGY

Nestle

$86.20

1.1 (1.29%)

QCOM

Qualcomm

$68.25

2.87 (4.39%)

AVGO

Broadcom

$263.25

-1.04 (-0.39%)

GM

General Motors

$44.19

0.12 (0.27%)

HAWK

Blackhawk

$45.08

8.575 (23.49%)

SCOR

comScore

$24.45

-4.65 (-15.98%)

UAA

Under Armour; also tag UA

$13.82

-1.305 (-8.63%)

UA

Under Armour; also tag UAA

$12.48

-1.665 (-11.78%)

NXPI

NXP Semiconductors

$119.40

-0.18 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 06

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

XON

Intrexon

$13.78

-0.935 (-6.36%)

16:16
01/16/18
01/16
16:16
01/16/18
16:16
Syndicate
Intrexon files to sell common stock, no amount given »

JMP Securities LLC is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
01/16/18
01/16
16:16
01/16/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MET

MetLife

$51.85

-1.48 (-2.78%)

16:16
01/16/18
01/16
16:16
01/16/18
16:16
Hot Stocks
MetLife to merger General American Life with and into Metropolitan Tower »

MetLife announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 12

    Jun

OSTK

Overstock.com

$70.25

-8.7 (-11.02%)

, KODK

Kodak

$8.43

-0.775 (-8.42%)

16:13
01/16/18
01/16
16:13
01/16/18
16:13
Hot Stocks
Overstock's tZERO to trade KODAKCoin on future security token trading platform »

Overstock.com's…

OSTK

Overstock.com

$70.25

-8.7 (-11.02%)

KODK

Kodak

$8.43

-0.775 (-8.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$17.52

-0.045 (-0.26%)

16:13
01/16/18
01/16
16:13
01/16/18
16:13
Hot Stocks
eHealth CFO David Francis to transition to role of Chief Operating Officer »

eHealth announced changes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$17.52

-0.045 (-0.26%)

16:12
01/16/18
01/16
16:12
01/16/18
16:12
Earnings
eHealth sees FY17 adjusted EBITDA ($15.5M)-($14.5M) »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$17.52

-0.045 (-0.26%)

16:12
01/16/18
01/16
16:12
01/16/18
16:12
Hot Stocks
eHealth acquires GoMedigap for $20M »

eHealth announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCBS

Nicolet Bankshares

$54.06

-1.82 (-3.26%)

16:11
01/16/18
01/16
16:11
01/16/18
16:11
Earnings
Nicolet Bankshares reports Q4 EPS 88c, consensus 81c »

Reports return on average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$17.52

-0.045 (-0.26%)

16:11
01/16/18
01/16
16:11
01/16/18
16:11
Earnings
eHealth sees Q4 adjusted EBITDA ($19.3M)-($18.3M) »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$37.00

-0.5 (-1.33%)

16:10
01/16/18
01/16
16:10
01/16/18
16:10
Hot Stocks
Mid Penn Bancorp, First Priority Financial Corp agree to merge »

Mid Penn Bancorp and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.95

0.0512 (5.71%)

16:10
01/16/18
01/16
16:10
01/16/18
16:10
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$4.65

-0.285 (-5.78%)

16:10
01/16/18
01/16
16:10
01/16/18
16:10
Hot Stocks
Tahoe Resources announces record gold production of 445,000 ounces in 2017 »

Tahoe Resources reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.